Previous 10 | Next 10 |
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...
2024-04-02 16:43:27 ET Gainers: Sight Sciences ( SGHT ) +19% . Zapata Computing Holdings ( ZPTA ) +9% . Cal-Maine Foods ( CALM ) +6% . Vanda Pharmaceuticals ( VNDA ) +5% . iHeartMedia ( IHRT ) +5% . Losers: Ac...
2024-03-14 16:55:37 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts Roche ends AC Immune partnership for Alzheimer’s drugs AC Immune issues updates on Phase 2 studies, cash runway Read the full article on Seekin...
2024-03-14 07:12:31 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts Roche ends AC Immune partnership for Alzheimer’s drugs AC Immune issues updates on Phase 2 studies, cash runway Seeking Alpha’s Quant Rati...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2 ACI-24.060 for Alzheim...
2024-01-22 08:52:21 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 studies, cash runway AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating o...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative di...
2024-01-03 09:23:46 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune SA Company Name:
ACIU Stock Symbol:
NASDAQ Market:
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday. Shares of RH (NYSE:RH) fell sharply in today&...
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday...